Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Absolute Lymphocyte Count
66%
Adjuvant Chemotherapy
11%
Binary Scale
11%
Clinical High Risk
11%
Clinical Trials
11%
Continuous Scale
22%
Cox Proportional Hazards Model
11%
Disease-free Survival
11%
Lymphopenia
22%
Malignancy
11%
Neoadjuvant Chemotherapy
11%
Neutrophil-to-lymphocyte Ratio
100%
Overall Survival
33%
Peripheral Blood
11%
Poor Outcome
11%
Radiation Chemotherapy
11%
Radiation Therapy
22%
Retrospective Analysis
11%
Standard-of-care Therapy
11%
Survival Outcomes
11%
Survival Prediction
100%
Time Effect
11%
Time-dependent Covariates
11%
Treatment Completion
22%
Treatment Course
11%
Triple-negative Breast Cancer
100%
University of Washington
11%
Nursing and Health Professions
Adjuvant Chemotherapy
11%
Disease Free Survival
11%
Health Care Quality
11%
Lymphocyte Count
66%
Lymphocytopenia
22%
Neoadjuvant Chemotherapy
11%
Neutrophil Lymphocyte Ratio
100%
Overall Survival
33%
Proportional Hazards Model
11%
Radiotherapy
22%
Triple Negative Breast Cancer
100%
Medicine and Dentistry
Adjuvant Chemotherapy
6%
Cancer
6%
Clinical Trial
6%
Disease Free Survival
6%
Lymphocyte
100%
Lymphocytopenia
13%
Neoadjuvant Chemotherapy
6%
Neutrophil
100%
Overall Survival
20%
Proportional Hazards Model
6%
Radiation Therapy
13%
Triple Negative Breast Cancer
100%
Immunology and Microbiology
Disease Free Survival
11%
Lymphocyte
100%
Lymphocyte Count
66%
Lymphocytopenia
22%
Neutrophil
100%
Overall Survival
33%
Mathematics
Covariate
100%
Cox Proportional Hazards Model
100%
Retrospective Analysis
100%
Neuroscience
Lymphocyte
100%
Lymphocytopenia
13%
Radiation Therapy
13%